Deprince Race & Zollo Inc. Purchases 145,062 Shares of Maximus, Inc. $MMS

Deprince Race & Zollo Inc. raised its position in shares of Maximus, Inc. (NYSE:MMS) by 147.1% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 243,695 shares of the health services provider’s stock after buying an additional 145,062 shares during the period. Deprince Race & Zollo Inc. owned about 0.43% of Maximus worth $22,266,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also modified their holdings of the company. Parkside Financial Bank & Trust grew its position in Maximus by 21.7% during the 2nd quarter. Parkside Financial Bank & Trust now owns 879 shares of the health services provider’s stock worth $62,000 after acquiring an additional 157 shares during the last quarter. GAMMA Investing LLC boosted its stake in Maximus by 13.9% in the third quarter. GAMMA Investing LLC now owns 1,337 shares of the health services provider’s stock worth $122,000 after purchasing an additional 163 shares in the last quarter. Trust Point Inc. grew its holdings in shares of Maximus by 3.7% during the third quarter. Trust Point Inc. now owns 5,286 shares of the health services provider’s stock worth $483,000 after purchasing an additional 191 shares during the last quarter. Verus Financial Partners Inc. increased its stake in shares of Maximus by 6.7% in the second quarter. Verus Financial Partners Inc. now owns 3,387 shares of the health services provider’s stock valued at $244,000 after buying an additional 214 shares in the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Maximus by 0.6% in the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 34,476 shares of the health services provider’s stock valued at $2,351,000 after buying an additional 221 shares during the last quarter. 97.21% of the stock is owned by institutional investors and hedge funds.

Maximus Stock Performance

Shares of NYSE:MMS opened at $86.93 on Friday. The company has a current ratio of 1.64, a quick ratio of 1.64 and a debt-to-equity ratio of 0.77. Maximus, Inc. has a 1-year low of $63.77 and a 1-year high of $92.50. The stock has a market capitalization of $4.73 billion, a P/E ratio of 15.63 and a beta of 0.56. The business has a 50-day moving average price of $84.83 and a two-hundred day moving average price of $81.84.

Maximus (NYSE:MMS) last issued its earnings results on Thursday, November 20th. The health services provider reported $1.62 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.63 by ($0.01). The business had revenue of $1.32 billion during the quarter, compared to the consensus estimate of $1.34 billion. Maximus had a net margin of 5.87% and a return on equity of 25.23%. The firm’s revenue for the quarter was up .2% compared to the same quarter last year. During the same period last year, the business posted $1.46 EPS. Maximus has set its FY 2026 guidance at 7.950-8.250 EPS. Equities analysts predict that Maximus, Inc. will post 6.15 earnings per share for the current year.

Maximus Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, December 1st. Shareholders of record on Friday, November 14th were given a dividend of $0.30 per share. The ex-dividend date was Friday, November 14th. This represents a $1.20 annualized dividend and a dividend yield of 1.4%. Maximus’s payout ratio is presently 21.58%.

Insider Buying and Selling at Maximus

In other news, insider Michelle F. Link sold 4,039 shares of the firm’s stock in a transaction on Wednesday, December 3rd. The stock was sold at an average price of $86.84, for a total value of $350,746.76. Following the transaction, the insider directly owned 19,542 shares in the company, valued at $1,697,027.28. This trade represents a 17.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. 1.60% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of brokerages have commented on MMS. Zacks Research lowered shares of Maximus from a “strong-buy” rating to a “hold” rating in a report on Monday, October 27th. Weiss Ratings reissued a “buy (b-)” rating on shares of Maximus in a research note on Monday, December 22nd. Two equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $90.00.

About Maximus

Maximus, Inc (NYSE: MMS) is a global provider of government services focused on delivering health and human services programs. The company partners with federal, state, and local agencies to administer and manage programs that support individuals and families across various stages of life. Key service areas include eligibility determination and enrollment services for Medicaid, Medicare, Children’s Health Insurance Program (CHIP) and other public assistance programs, as well as call center operations, case management and program integrity solutions.